Karyopharm Therapeutics (KPTI) EPS (Basic) Growth (3y) (2015 - 2026)
Powered by 
Analysis
Karyopharm Therapeutics (KPTI) EPS (Basic) Growth (3y) (2015 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 641.02 Bn | 620.27 Bn | 17.26 Bn | 5.11% |
| 2 | AbbVie | 445.75 Bn | 439.18 Bn | 12.70 Bn | 21.23% |
| 3 | Merck | 357.52 Bn | 350.38 Bn | 12.21 Bn | 38.72% |
| 4 | Novartis Ag | 267.31 Bn | 259.62 Bn | 11.24 Bn | 14.72% |
| 5 | Pfizer | 156.58 Bn | 144.88 Bn | 10.94 Bn | -28.08% |
| 6 | Sanofi | 52.14 Bn | 44.75 Bn | 10.79 Bn | -36.03% |
| 7 | Revolution Medicines | 43.04 Bn | 43.04 Bn | - | - |
| 8 | Incyte | 24.61 Bn | 20.07 Bn | 1.57 Bn | 47.44% |
| 9 | United Therapeutics | 21.30 Bn | 18.64 Bn | 683.80 Mn | 12.25% |
| 10 | Karyopharm Therapeutics | 46.59 Mn | -18.51 Mn | 32.35 Mn | 18.54% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 18.54% |
| Dec 31, 2025 | 8.26% |
| Sep 30, 2025 | 17.45% |
| Jun 30, 2025 | 22.37% |
| Mar 31, 2025 | 29.79% |
| Dec 31, 2024 | -35.58% |
| Sep 30, 2024 | 27.97% |
| Jun 30, 2024 | 31.54% |
| Mar 31, 2024 | 25.11% |
| Dec 31, 2023 | 15.13% |
| Sep 30, 2023 | 25.46% |
| Jun 30, 2023 | 23.33% |
| Mar 31, 2023 | 29.39% |
| Dec 31, 2022 | 15.04% |
| Sep 30, 2022 | 12.07% |
| Jun 30, 2022 | 4.74% |
| Mar 31, 2022 | 21.11% |
| Dec 31, 2021 | 35.75% |
| Sep 30, 2021 | 4.71% |
| Jun 30, 2021 | -5.90% |